Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Japanese cGVHD
NCT03474679Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03474679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474679.